MedTrace Logo

Pharmaceutical Care for Patients Using Capecitabine

NCT07063706 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2025-07-18

No results posted yet for this study

Summary

This is a longitudinal, prospective and intervention study, which will be carried out with patients undergoing treatment with capecitabine, where the impact of pharmaceutical care will be evaluated.

Conditions

  • Cancer Colorectal
  • Cancer Gi
  • Capecitabine
  • Pharmaceutical Services
  • Adverse Drug Reaction (ADR)

Interventions

OTHER

Pharmaceutical Care

Participants in the intervention group received pharmaceutical care

Sponsors & Collaborators

  • Universidade Federal Fluminense

    collaborator OTHER

  • Instituto Nacional de Cancer, Brazil

    collaborator OTHER_GOV

  • Universidade Federal do Rio de Janeiro

    collaborator OTHER

  • Faculdade de Farmácia

    lead OTHER

Principal Investigators

  • CAMILLE C NIGRI, PhD · Universidade Federal do Rio de Janeiro

  • THAISA A NOGUEIRA, PhD · Universidade Federal Fluminense

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2024-03-31
Completion
2024-08-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07063706 on ClinicalTrials.gov